ERBB2 and cancer: The median survival time from first radiotherapy for BRM was 5.1 months in the overall cohort and 4.8 months for HR-positive/ERBB2-negative cancer, 8.7 months for ERBB2-positive/HR-positive cancer, 9.4 months for ERBB2-positive/HR-negative cancer, 2.6 months for TNBC, and 3.9 months for the unknown subtype cohort (Table 2).